References
1. Smith TJ, Hegedüs L. Graves’ Disease. N Engl J Med . 2016;375(16):1552-1565.
2. Bartalena L, Baldeschi L, Boboridis K, et al. The 2016 European Thyroid Association/European Group on Graves’ Orbitopathy Guidelines for the Management of Graves’ Orbitopathy. Eur Thyroid J . 2016;5(1):9-26.
3. Seo BF, Kang KJ, Jung S-N, Byeon JH. Skeletal cavernous hemangiomas of the frontal bone with orbital roof and rim involvement. Arch Craniofac Surg . 2018;19(3):214-217.
4. Cheng N-C, Lai D-M, Hsie M-H, Liao S-L, Chen Y-BT. Intraosseous hemangiomas of the facial bone. Plast Reconstr Surg . 2006;117(7):2366-2372.
5. Ueda-Sakane Y, Kanamoto N, Fushimi Y, et al. Overall safety and efficacy of high-dose and low-dose intravenous glucocorticoid therapy in patients with moderate-to-severe active Graves’ ophthalmopathy.Endocr J . 2016;63(8):703-714.